Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants

Gretel Terrero; Jashodeep Datta; Jessica Dennison; Daniel A Sussman; Ines Lohse; Nipun B Merchant; Peter J Hosein

doi:10.1001/jamaoncol.2022.0611

Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants

JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.

Authors

Gretel Terrero¹, Jashodeep Datta¹, Jessica Dennison¹, Daniel A Sussman¹, Ines Lohse¹, Nipun B Merchant¹, Peter J Hosein¹

Affiliation

¹ Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.

Abstract

This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD) pathogenic germline variants (PGVs).

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Biliary Tract Neoplasms* / drug therapy
Biliary Tract Neoplasms* / genetics
Carcinoma, Renal Cell* / drug therapy
Germ Cells
Homologous Recombination
Humans
Ipilimumab / adverse effects
Kidney Neoplasms*
Nivolumab / therapeutic use

Substances

Ipilimumab
Nivolumab